Hong-Wei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hong-Wei Wang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Li Zhang
4 shared publicationsLei Zhu
3 shared publicationsLi Zhang
3 shared publicationsYan-Hong Tan
3 shared publicationsJing Xu
2 shared publicationsJun-Zhong Sun
Department of Oncology, The First Affiliated Hospital of General Hospital of Chinese PLA, Beijing 100853, China
2 shared publications
Latest Publications
- 1 January 2014
- Vol. 35 (1) , 80-6
The effects of subclinical hypothyroidism on serum lipid level and TLR4 expression of monocyte in peripheral blood of rats.
To observe effect of subclinical hypothyroidism (SCH) on serum lipid level and expression of toll-like receptor 4 (TLR4) in rats' peripheral blood mononuclear cells (PBMC). Fifty Wistar female rats were divided into three groups: normal control (NC group; n=10), sham group (n=10), and L-T-4 (L-thyroxine) group (n=30, with thyroidectomy, fed with rich-calcium water after operation. 5 weeks later, abdominal subcutaneous injection of L-T-4: 0.95 μg/100g/d). 8 weeks later, the rats were killed then the peripheral blood was collected to determine the levels of serum thyroid-stimulating hormone (TSH), total thyroid hormone (TT4), total cholesterol (TC) and low density lipoprotein cholesterin (LDL-C). Rats in L-T-4 group were divided into normal lipid (NL) group) and high lipid (HL) group) according to lipid value of NC group. Monocytes were separated from blood to determine TLR4 expression by flow cytometry. In NL and HL groups TSH were higher than in NC and Sham groups (p0.05). TLR4, TLR4 mRNA, NF-κB (p65) were increased (p0.05). TLR4, TLR4 mRNA, NF-κB (p65) of PBMC and TNF-α, IL-6, IL-1β expression in serum were all increased in SCH rats, which was not related to serum dyslipidemia.
- 1 January 2014
- Vol. 35 (1) , 80-6
The effects of subclinical hypothyroidism on serum lipid level and TLR4 expression of monocyte in peripheral blood of rats.
To observe effect of subclinical hypothyroidism (SCH) on serum lipid level and expression of toll-like receptor 4 (TLR4) in rats' peripheral blood mononuclear cells (PBMC). Fifty Wistar female rats were divided into three groups: normal control (NC group; n=10), sham group (n=10), and L-T-4 (L-thyroxine) group (n=30, with thyroidectomy, fed with rich-calcium water after operation. 5 weeks later, abdominal subcutaneous injection of L-T-4: 0.95 μg/100g/d). 8 weeks later, the rats were killed then the peripheral blood was collected to determine the levels of serum thyroid-stimulating hormone (TSH), total thyroid hormone (TT4), total cholesterol (TC) and low density lipoprotein cholesterin (LDL-C). Rats in L-T-4 group were divided into normal lipid (NL) group) and high lipid (HL) group) according to lipid value of NC group. Monocytes were separated from blood to determine TLR4 expression by flow cytometry. In NL and HL groups TSH were higher than in NC and Sham groups (p0.05). TLR4, TLR4 mRNA, NF-κB (p65) were increased (p0.05). TLR4, TLR4 mRNA, NF-κB (p65) of PBMC and TNF-α, IL-6, IL-1β expression in serum were all increased in SCH rats, which was not related to serum dyslipidemia.
- 19 January 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (1) , 1-7
Attenuated Salmonella typhimurium carrying the hepatocyte growth factor and keratinocyte growth factor genes repairs gastrointestinal mucosal damage caused by chemotherapy
Radiotherapy and chemotherapy are the main therapeutic approaches for patients with malignant tumours, especially advanced tumours. However, they can cause adverse effects, one of which is gastrointestinal mucosal damage, which can greatly affect patients’ quality of life. Until now, there have been no effective therapies to avoid or treat these adverse effects. In this study, we used attenuated Salmonella typhimurium (S. typhimurium) to deliver the hepatocyte growth factor (HGF) or keratinocyte growth factor (KGF) to murine gastrointestinal mucosa. We found that attenuated S. typhimurium carrying the HGF or KGF genes can effectively reduce the ratio of tumour to non-tumour carcass weight, repair damage to the gastrointestinal mucosal from chemotherapy, improve the immune response, and reduce the mortality rate of mice. Oral administration of attenuated S. typhimurium with HGF and KGF may be promising as a way of improving the quality of life of patients undergoing radiotherapy and chemotherapy.
- 19 January 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (1) , 1-7
Attenuated Salmonella typhimurium carrying the hepatocyte growth factor and keratinocyte growth factor genes repairs gastrointestinal mucosal damage caused by chemotherapy
Radiotherapy and chemotherapy are the main therapeutic approaches for patients with malignant tumours, especially advanced tumours. However, they can cause adverse effects, one of which is gastrointestinal mucosal damage, which can greatly affect patients’ quality of life. Until now, there have been no effective therapies to avoid or treat these adverse effects. In this study, we used attenuated Salmonella typhimurium (S. typhimurium) to deliver the hepatocyte growth factor (HGF) or keratinocyte growth factor (KGF) to murine gastrointestinal mucosa. We found that attenuated S. typhimurium carrying the HGF or KGF genes can effectively reduce the ratio of tumour to non-tumour carcass weight, repair damage to the gastrointestinal mucosal from chemotherapy, improve the immune response, and reduce the mortality rate of mice. Oral administration of attenuated S. typhimurium with HGF and KGF may be promising as a way of improving the quality of life of patients undergoing radiotherapy and chemotherapy.
- 1 July 2012
- Vol. 125 (14) , 2638-40
Massive hemoptysis and hemothorax: a rare but fatal complication of intralobar sequestration.
Intralobar sequestration (ILS) is an uncommon abnormality that accounts for 75% of all pulmonary sequestrations. Over the years there have been several reports of various presenting signs of which hemoptysis was commonly described, however, massive hemoptysis and hemothorax is extremely rare in literature. We present a case of a 45-year-old man who died of fatal complication from an ILS. This case report shows an uncommon presentation of ILS with massive hemoptysis and hemothorax resulting in a dramatic course of disease and a fatal outcome, and for this reason in the absence of trauma or other causes for massive hemoptysis, hemothorax, or lung hematoma, this possibility should be kept in mind so as to avoid misdiagnosis, and resection of the sequestered tissue should be considered in all patients.
- 1 July 2012
- Vol. 125 (14) , 2638-40
Massive hemoptysis and hemothorax: a rare but fatal complication of intralobar sequestration.
Intralobar sequestration (ILS) is an uncommon abnormality that accounts for 75% of all pulmonary sequestrations. Over the years there have been several reports of various presenting signs of which hemoptysis was commonly described, however, massive hemoptysis and hemothorax is extremely rare in literature. We present a case of a 45-year-old man who died of fatal complication from an ILS. This case report shows an uncommon presentation of ILS with massive hemoptysis and hemothorax resulting in a dramatic course of disease and a fatal outcome, and for this reason in the absence of trauma or other causes for massive hemoptysis, hemothorax, or lung hematoma, this possibility should be kept in mind so as to avoid misdiagnosis, and resection of the sequestered tissue should be considered in all patients.
- 1 March 2010
- Vol. 31 (3) , 172-5
[Expression of WT1 gene in CD34(+)CD38(-)CD123(+) AML stem cells and its significance analysis.].
To investigate whether WT1 gene overexpressed in leukemic stem cells (LSCs) and its significance. Expression of WT1(+17AA) and WT1(+KTS) gene isoforms in CD34(+)CD38(-)CD123(+) cells (LSCs) of 47 AML patients were determined by fluorescence quantitative RT-PCR. The ratio of the four splicing isoforms WT1(+/+), WT1(+/-), WT1(-/+) and WT1(-/-) in LSCs were calculated and compared with that in normal CD34(+)CD38(-)CD123(-) cells (HSCs). The relationship in AML patients between LSCs WT1 expression and remission rate, survival time and relapse rate was analyzed. The expression of WT1 gene was highest (0.034 +/- 0.034) in LSCs, and higher in CD34(+)CD38(-)CD123(-) AML cells as compared with that in HSCs (P < 0.05). The proportion of +17AA isoform was predominant over -17AA in all the three cell subsets with no difference. The proportion of +KTS isoform was the highest in HSCs (0.57 +/- 0.04), while the lowest in CD34(+)CD38(-)CD123(-)AML cells (0.50 +/- 0.12) (P < 0.05). No significant difference in the four isoforms expression ratio was observed among the three groups. WT1 expression in LSCs was not correlated with sex, age, FAB subtype and blast cell ratio, while the ratio of CD34(+) cells in blast cell was significantly higher in the WT1 high expression group than in the low expression group (P < 0.01). The CR rate was significantly lower in WT1 high expression group (21.1%) than in the WT1 low expression group (59.1%) (P < 0.05). The follow-up data were available in 41 patients with a median follow-up duration of 118 (3 - 290) days. The median overall survival (OS) for WT1 high and low expression group were 77\[95% confident interval (CI) 45 - 108\], 158 (95%CI 100 - 215) days respectively (P = 0.041). WT1 gene overexpressed in AML LSCs and the ratios of four WT1 isoforms have no difference in LSC compared with HSC. Patients with higher LSC WT1 expression have lower CR rate and shorter survival time.- 1 March 2010
- Vol. 31 (3) , 172-5
[Expression of WT1 gene in CD34(+)CD38(-)CD123(+) AML stem cells and its significance analysis.].
To investigate whether WT1 gene overexpressed in leukemic stem cells (LSCs) and its significance. Expression of WT1(+17AA) and WT1(+KTS) gene isoforms in CD34(+)CD38(-)CD123(+) cells (LSCs) of 47 AML patients were determined by fluorescence quantitative RT-PCR. The ratio of the four splicing isoforms WT1(+/+), WT1(+/-), WT1(-/+) and WT1(-/-) in LSCs were calculated and compared with that in normal CD34(+)CD38(-)CD123(-) cells (HSCs). The relationship in AML patients between LSCs WT1 expression and remission rate, survival time and relapse rate was analyzed. The expression of WT1 gene was highest (0.034 +/- 0.034) in LSCs, and higher in CD34(+)CD38(-)CD123(-) AML cells as compared with that in HSCs (P < 0.05). The proportion of +17AA isoform was predominant over -17AA in all the three cell subsets with no difference. The proportion of +KTS isoform was the highest in HSCs (0.57 +/- 0.04), while the lowest in CD34(+)CD38(-)CD123(-)AML cells (0.50 +/- 0.12) (P < 0.05). No significant difference in the four isoforms expression ratio was observed among the three groups. WT1 expression in LSCs was not correlated with sex, age, FAB subtype and blast cell ratio, while the ratio of CD34(+) cells in blast cell was significantly higher in the WT1 high expression group than in the low expression group (P < 0.01). The CR rate was significantly lower in WT1 high expression group (21.1%) than in the WT1 low expression group (59.1%) (P < 0.05). The follow-up data were available in 41 patients with a median follow-up duration of 118 (3 - 290) days. The median overall survival (OS) for WT1 high and low expression group were 77\[95% confident interval (CI) 45 - 108\], 158 (95%CI 100 - 215) days respectively (P = 0.041). WT1 gene overexpressed in AML LSCs and the ratios of four WT1 isoforms have no difference in LSC compared with HSC. Patients with higher LSC WT1 expression have lower CR rate and shorter survival time.- 1 June 2009
- Vol. 30 (6) , 373-6
[The effects of WT1 gene down regulation on the sensitivity of K562/A02 cells to adriamycin].
To investigate the effects of WT1 gene down regulation on the sensitivity of K562/A02 cells to adriamycin (ADM). Short hair RNA (shRNA) plasmid vector targeting WT1 gene with enhanced green fluorescent protein (EGFP) was transfected into K562/A02 cells. Transfection efficiency was detected and transfected cells were sorted by flow cytometry. Expression of WT1 gene was detected by real time fluorescence RT-PCR and Western blot. The IC50 of ADM on K562/A02 cells was measured by MTT assay. Intracellular ADM accumulation and ADM-induced apoptosis of K562/A02 cells were detected by flow cytometry. 48 h after transfection,the transfection efficiency was (68.2 +/- 4.5)%. Both the mRNA and protein of WT1 were significantly decreased in K562/A02 cells transfected with WT1 shRNA plasmid than in control. After 24 h ADM induction, the relative reverse rate of sensitivity of K562/A02 cells to ADM was 71.5%. The intracellular accumulation of ADM was greatly increased (P<0.05) and ADM-induced apoptosis rate elevated from 10.4% to 67.3% (P<0.05). shRNA targeting WT1 gene can efficiently inhibit the WT1 expression in K562/A02 cells and enhance the drug sensitivity of K562 cells to ADM.
- 1 June 2009
- Vol. 30 (6) , 373-6
[The effects of WT1 gene down regulation on the sensitivity of K562/A02 cells to adriamycin].
To investigate the effects of WT1 gene down regulation on the sensitivity of K562/A02 cells to adriamycin (ADM). Short hair RNA (shRNA) plasmid vector targeting WT1 gene with enhanced green fluorescent protein (EGFP) was transfected into K562/A02 cells. Transfection efficiency was detected and transfected cells were sorted by flow cytometry. Expression of WT1 gene was detected by real time fluorescence RT-PCR and Western blot. The IC50 of ADM on K562/A02 cells was measured by MTT assay. Intracellular ADM accumulation and ADM-induced apoptosis of K562/A02 cells were detected by flow cytometry. 48 h after transfection,the transfection efficiency was (68.2 +/- 4.5)%. Both the mRNA and protein of WT1 were significantly decreased in K562/A02 cells transfected with WT1 shRNA plasmid than in control. After 24 h ADM induction, the relative reverse rate of sensitivity of K562/A02 cells to ADM was 71.5%. The intracellular accumulation of ADM was greatly increased (P<0.05) and ADM-induced apoptosis rate elevated from 10.4% to 67.3% (P<0.05). shRNA targeting WT1 gene can efficiently inhibit the WT1 expression in K562/A02 cells and enhance the drug sensitivity of K562 cells to ADM.
- 1 February 2009
- Vol. 17 (1) , 36-9
[Analysis of immunophenotype, lymphocytic subsets and NK cells in patients with B cell chronic lymphoid leukemia].
The aim of this study was to evaluate the values of immunophenotype of leukemic cells in bone marrow (BM) or peripheral blood (PB), lymphocytic subsets and NK cells of PB in diagnosis, therapy and prognosis of patients with B cell chronic lymphoid leukemia (B-CLL). The samples of PB and BM from 67 patients with B-CLL were collected and detected by multi-parameter flow cytometry. The results showed that the percentage of lymphocytes in PB of 67 patients with B-CLL obviously increased, as compared with normal persons, while CD3, CD4, CD8 and NK cells decreased significantly (p < 0.01), and no CD4/CD8 ratio had notable change (p > 0.05). In their immunophenotype results, the positive expression rate of CD19 was highest (91.04%), followed by CD5 (80.60%), CD 20 (76.12), cyCD 79a (74.63%), CD 38 (43.28%), CD 11c (42.86%), CD 7 (41.94%), ZAP-70 (39.29%), CD25 (0.00%); co-expression rate of CD5 and CD19 was 72.73%; the expression of ZAP-70 was correlated with CD 38 (p < 0.05). In conclusion, detection of cell immunophenotypes, lymphocytic subsets in PB and BM and NK cells in PB contribute to diagnosis of patients with B-CLL.
- 1 February 2009
- Vol. 17 (1) , 36-9
[Analysis of immunophenotype, lymphocytic subsets and NK cells in patients with B cell chronic lymphoid leukemia].
The aim of this study was to evaluate the values of immunophenotype of leukemic cells in bone marrow (BM) or peripheral blood (PB), lymphocytic subsets and NK cells of PB in diagnosis, therapy and prognosis of patients with B cell chronic lymphoid leukemia (B-CLL). The samples of PB and BM from 67 patients with B-CLL were collected and detected by multi-parameter flow cytometry. The results showed that the percentage of lymphocytes in PB of 67 patients with B-CLL obviously increased, as compared with normal persons, while CD3, CD4, CD8 and NK cells decreased significantly (p < 0.01), and no CD4/CD8 ratio had notable change (p > 0.05). In their immunophenotype results, the positive expression rate of CD19 was highest (91.04%), followed by CD5 (80.60%), CD 20 (76.12), cyCD 79a (74.63%), CD 38 (43.28%), CD 11c (42.86%), CD 7 (41.94%), ZAP-70 (39.29%), CD25 (0.00%); co-expression rate of CD5 and CD19 was 72.73%; the expression of ZAP-70 was correlated with CD 38 (p < 0.05). In conclusion, detection of cell immunophenotypes, lymphocytic subsets in PB and BM and NK cells in PB contribute to diagnosis of patients with B-CLL.
- 1 January 2008
- Vol. 29 (1) , 44-7
[Relationship between the long type PML-RAR alpha and the prognosis of patients with acute promyelocytic leukemia].
To explore the relationship between long (L) type PML-RAR alpha fusion gene and the prognosis of patients with acute promyelocytic leukemia (APL). PML-RAR alpha fusion gene was detected by RT-PCR in 33 APL patients. The optical density of three bands including E5 (+) E6 (+) 636 bp (no deletion), E5 (-) E6 (+) 492 bp (exon 5 deleted) and E5 (-) E6 (-) 232 bp (both exon 5 and exon 6 deleted) was measured by a UVP analysis system and their relative proportions were calculated. The relative expression level of each splicing band, initial WBC count and age were statistically (for single and multi-factor analysis) analyzed with prognosis. The relative expressions of E5 (-) E6 (+) and E5 (-) E6 (-) in death group were obviously different from that in first complete remission (CR1) group (P < 0.01), but do not for E5 (+) E6 (+) (P > 0.05). The relative expression levels of E5 (-) E6 (+), E5 (-) E6 (-) and E5 (+) E6 (+) were 0.23 +/- 0.12, 0.58 +/- 0.18, 0.20 +/- 0.09 in death group, and 0.45 +/- 0.16, 0.23 +/- 0.12, 0.31 +/- 0.16 in CR1 group, respectively. Initial WBC count and age was no difference between the two groups (P > 0.05). Logistic regression analysis showed that the expression of E5 (-) E6 (+) had no effect on the prognosis (B = 3.475, P = 0.492), but the expression of E5 (-) E6 (-) showed a negative correlation with prognosis (B = -19.660, P = 0.046). The high expression of E5 (-) E6 (-) is correlated with the poor prognosis for patients with APL.
- 1 January 2008
- Vol. 29 (1) , 44-7
[Relationship between the long type PML-RAR alpha and the prognosis of patients with acute promyelocytic leukemia].
To explore the relationship between long (L) type PML-RAR alpha fusion gene and the prognosis of patients with acute promyelocytic leukemia (APL). PML-RAR alpha fusion gene was detected by RT-PCR in 33 APL patients. The optical density of three bands including E5 (+) E6 (+) 636 bp (no deletion), E5 (-) E6 (+) 492 bp (exon 5 deleted) and E5 (-) E6 (-) 232 bp (both exon 5 and exon 6 deleted) was measured by a UVP analysis system and their relative proportions were calculated. The relative expression level of each splicing band, initial WBC count and age were statistically (for single and multi-factor analysis) analyzed with prognosis. The relative expressions of E5 (-) E6 (+) and E5 (-) E6 (-) in death group were obviously different from that in first complete remission (CR1) group (P < 0.01), but do not for E5 (+) E6 (+) (P > 0.05). The relative expression levels of E5 (-) E6 (+), E5 (-) E6 (-) and E5 (+) E6 (+) were 0.23 +/- 0.12, 0.58 +/- 0.18, 0.20 +/- 0.09 in death group, and 0.45 +/- 0.16, 0.23 +/- 0.12, 0.31 +/- 0.16 in CR1 group, respectively. Initial WBC count and age was no difference between the two groups (P > 0.05). Logistic regression analysis showed that the expression of E5 (-) E6 (+) had no effect on the prognosis (B = 3.475, P = 0.492), but the expression of E5 (-) E6 (-) showed a negative correlation with prognosis (B = -19.660, P = 0.046). The high expression of E5 (-) E6 (-) is correlated with the poor prognosis for patients with APL.
- 1 June 2007
- Vol. 15 (3) , 603-6
[WT1 gene expression and its isoform ratio in different cell subsets of normal human bone marrow].
The Wilms' tumor gene (WT1) is a transcription factor involved in tumorigenesis, especially in leukemogenesis. However, the role of WT1 expression in nonmalignant hematopoietic cells remains unclear. Furthermore, due to alternative splicing at two sites: 17 amino acid residues of exon 5 (+17AA) and 3 amino acid residues (+KTS) between exons 9 and 10, WT1 gene has four main isoforms (17AA+/KTS+, 17AA+/KTS-, 17AA-/KTS+, 17AA-/KTS-, abbreviation: +/+, +/-, -/+, -/-). The isoforms probably existed in hematopoietic cells, which make the research more complex. The aim of study was to elucidate the expression and its isoforms of WT1 gene in different cell subsets of healthy bone marrow donors. The fluorescence RT-PCR detection system was established to measure the expressions of full-length WT1, WT1 (+17AA) and WT1 (+KTS) in CD34(+)CD38(-) (stem cell), CD34(+)CD38(+) (progenitor cell), CD15(+)CD11b(+) (granulocyte), CD33(+)CD14(+) (monocyte), CD20(+)CD5(-) (B-lymphocyte) and CD20(-)CD5(+) (T-lymphocyte) subsets from 18 normal human bone marrow samples. The results showed that WT1 expressed in CD34(+)CD38(-), CD34(+)CD38(+), CD15(+)CD11b(+) and CD33(+)CD14(+), but not in CD20(+)CD5(-) and CD20(-)CD5(+) subsets. The highest expression was in CD34(+)CD38(-), but decreased gradually in CD15(+)CD11b(+) and CD33(+)CD14(+) subsets. WT1 (+17AA), WT1 (+KTS) and WT1 (+/+) isoforms were predominant in CD34(+)CD38(-) and CD34(+)CD38(+) primitive subsets, while in CD15(+)CD11b(+) and CD33(+)CD14(+) the dominant isoforms were WT1 (-17AA), WT1 (-KTS) and WT1 (-/-). It is concluded that the expression of WT1 in normal bone marrow decreases gradually with cell differentiation. Hematopoietic cells may adjust the ratios of WT1 isoforms to inhibit or promote cell differentiation.
- 1 June 2007
- Vol. 15 (3) , 603-6
[WT1 gene expression and its isoform ratio in different cell subsets of normal human bone marrow].
The Wilms' tumor gene (WT1) is a transcription factor involved in tumorigenesis, especially in leukemogenesis. However, the role of WT1 expression in nonmalignant hematopoietic cells remains unclear. Furthermore, due to alternative splicing at two sites: 17 amino acid residues of exon 5 (+17AA) and 3 amino acid residues (+KTS) between exons 9 and 10, WT1 gene has four main isoforms (17AA+/KTS+, 17AA+/KTS-, 17AA-/KTS+, 17AA-/KTS-, abbreviation: +/+, +/-, -/+, -/-). The isoforms probably existed in hematopoietic cells, which make the research more complex. The aim of study was to elucidate the expression and its isoforms of WT1 gene in different cell subsets of healthy bone marrow donors. The fluorescence RT-PCR detection system was established to measure the expressions of full-length WT1, WT1 (+17AA) and WT1 (+KTS) in CD34(+)CD38(-) (stem cell), CD34(+)CD38(+) (progenitor cell), CD15(+)CD11b(+) (granulocyte), CD33(+)CD14(+) (monocyte), CD20(+)CD5(-) (B-lymphocyte) and CD20(-)CD5(+) (T-lymphocyte) subsets from 18 normal human bone marrow samples. The results showed that WT1 expressed in CD34(+)CD38(-), CD34(+)CD38(+), CD15(+)CD11b(+) and CD33(+)CD14(+), but not in CD20(+)CD5(-) and CD20(-)CD5(+) subsets. The highest expression was in CD34(+)CD38(-), but decreased gradually in CD15(+)CD11b(+) and CD33(+)CD14(+) subsets. WT1 (+17AA), WT1 (+KTS) and WT1 (+/+) isoforms were predominant in CD34(+)CD38(-) and CD34(+)CD38(+) primitive subsets, while in CD15(+)CD11b(+) and CD33(+)CD14(+) the dominant isoforms were WT1 (-17AA), WT1 (-KTS) and WT1 (-/-). It is concluded that the expression of WT1 in normal bone marrow decreases gradually with cell differentiation. Hematopoietic cells may adjust the ratios of WT1 isoforms to inhibit or promote cell differentiation.
- 1 February 2007
- Vol. 15 (1) , 59-62
[Apoptosis of HL-60 cells induced by recombinant common Buckwheat trypsin inhibitor].
The study was purposed to investigate the apoptosis of HL-60 cells induced by recombinant common buckwheat trypsin inhibitor (rBTI) and its mechanism. The inhibition rate of rBTI on HL-60 cells was detected by MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide); the morphology of HL-60 nuclei was observed by fluorescence microscopy; the apoptosis cells of HL-60 detected by agarose gel electrophoresis and the changes of apoptosis rate was assayed by flow cytometry (FCM), when the HL-60 cells were treated with different concentration of rBTI for 24 hours. The results showed that the growth of HL-60 cells was inhibited evidently after treatment with rBTI in a dose-dependent manner, but there were minimal effects on normal human peripheral blood mononuclear cells (PBMNCs). The nuclei of HL-60 cells showed the characteristics of apoptosis, the analysis by flow cytometry indicated that the apoptosis rate of HL-60 cells was 52% after treatment with rBTI (100 microg/ml), DNA analyzed by agarose gel electrophoresis showed "ladder" pattern. It is concluded that rBTI obviously inhibits growth of HL-60 and induces its apoptosis which provides a foundation for use of recombinant common buckwheat trypsin inhibitor to cure the acute myeloid leukemia.
- 1 February 2007
- Vol. 15 (1) , 59-62
[Apoptosis of HL-60 cells induced by recombinant common Buckwheat trypsin inhibitor].
The study was purposed to investigate the apoptosis of HL-60 cells induced by recombinant common buckwheat trypsin inhibitor (rBTI) and its mechanism. The inhibition rate of rBTI on HL-60 cells was detected by MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide); the morphology of HL-60 nuclei was observed by fluorescence microscopy; the apoptosis cells of HL-60 detected by agarose gel electrophoresis and the changes of apoptosis rate was assayed by flow cytometry (FCM), when the HL-60 cells were treated with different concentration of rBTI for 24 hours. The results showed that the growth of HL-60 cells was inhibited evidently after treatment with rBTI in a dose-dependent manner, but there were minimal effects on normal human peripheral blood mononuclear cells (PBMNCs). The nuclei of HL-60 cells showed the characteristics of apoptosis, the analysis by flow cytometry indicated that the apoptosis rate of HL-60 cells was 52% after treatment with rBTI (100 microg/ml), DNA analyzed by agarose gel electrophoresis showed "ladder" pattern. It is concluded that rBTI obviously inhibits growth of HL-60 and induces its apoptosis which provides a foundation for use of recombinant common buckwheat trypsin inhibitor to cure the acute myeloid leukemia.